Association of Interleukin-6 Haplotypes, Obesity, and Metabolic Abnormalities in a Population of Central Mexico
Abstract Objective: We undertook this study to determine the relationship among -174G>C and 598G>A polymorphisms in the promoter region of interleukin-6, obesity, and metabolic abnormalities in subjects from central Mexico. Methods: Included in the study were 150 subjects who were not first-degree relatives of patients with diabetes and 106 blood samples from the general population. All were genotyped using polymerase chain reaction (PCR) restriction fragment-length polymorphism. Logistic regression analysis was used to assess the relationships ...
Alpha 1-Antitrypsin. A Novel Biomarker for Obesity in Humans
Abstract Objective: To investigate the relationship between alpha 1-antitrypsin (A1AT), adiponectin, leptin, blood glucose, and insulin protein levels in human serum and obesity. Methods: Forty-eight subjects with normal blood glucose levels and average age of 32.4+/-5.1 years were enrolled in this study. The study took place in the Reproductive Center, The Second Hospital of Jilin University, Changchun, China between June and July 2011. The height and weight were measured for calculating the body mass index (BMI) and ...
Halberd and GTX Corp Sign Scientific Collaboration and Reseller Agreement
GTX and Halberd will begin collaborating on developing and testing treatments for Alzheimer’s Disease/PTSD and other neurological diseases and GTX will begin marketing Halberd’s VitaShieldMaxTM Immune Support through their online ecommerce platform. Jackson Center, PA, October 12, 2021 – Halberd Corporation (OTC-PINK: HALB) and GTX Corp (OTC-PINK: GTXO) have agreed to work together on various neurodegenerative diseases such as Alzheimer’s Disease, Parkinson’s Disease, PTSD/CTE (Chronic Traumatic Encephalopathy)/ Traumatic Brain Injury), among others. These diseases are ...
Halberd Corporation CEO Letter
Q3-21 Accomplishments and Q4 Plans Jackson Center, PA, October 7, 2021 Greetings From The CEO And Staff At HALBERD CORPORATION! (OTC-PINK: HALB) This past quarter, Halberd has made some very significant and unparalleled achievements developing treatments for neurodegenerative diseases, such as PTSD/ CTE (Post Traumatic Stress Disorder/Chronic Traumatic Encephalopathy), Alzheimer’s Disease, Parkinson’s Disease, etc. As reported in the last quarterly update, our research led us to investigate RF (Radio Frequency) and laser exposure, as the ...
Halberd’s VITASHIELDMAX(TM) Immunity Support Product Available on Amazon
Jackson Center, PA, October 5, 2021 – Halberd Corporation (OTC-PINK: "HALB") announced that its nutraceutical immune support product, VitaShieldMaxTM, is now available through Amazon, in addition to its availability through Halberd’s website at www.vitashieldmax.com. William A. Hartman, Halberd's Chairman, President & CEO, stated, “We are pleased that our product will now also be available through Amazon, and will be able to reach virtually anyone in need of immunity support to maintain their body’s health and ...
Halberd and heliosDX of RushNet Enter Scientific Collaboration Agreement
Agreement To Advance Healthcare Diagnostic Technologies Jackson Center, PA, September 22, 2021 – Halberd Corp. (OTC PINK: HALB) and heliosDx, a wholly owned company of Rush Net, Inc.(OTC PINK: RUSH), an Alpharetta, GA company, announce a Scientific Collaboration Agreement to explore synergies and opportunities mutually beneficial to both companies. A major objective of the agreement is to develop accurate and reliable diagnostic methods by sharing innovative ideas and technologies that will provide the foundation for ...